查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1298097

CAR-T细胞治疗市场、份额、规模、趋势、行业分析报告，按目标抗原（CD19/CD22、BCMA等）、按适应症、按地区、细分市场预测，2023-2032年

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 119 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，预计到2032年，全球CAR-T细胞治疗市场规模将达到1186.8068亿美元。 该报告提供了对当前市场动态的详细见解，并对未来市场增长进行了分析。

利用免疫系统对抗癌症，CAR-T 细胞疗法市场出现了显着增长。 这种突破性的方法修改患者自身的 T 细胞（一种白细胞），以在其表面表达嵌合抗原受体 (CAR)。 CAR 使 T 细胞能够识别并靶向癌细胞内的特定抗原，从而导致癌细胞被破坏。 CAR-T疗法在治疗某些血液恶性肿瘤方面显示出有希望的结果，并且正在研究其在其他类型癌症中的潜力。

CAR-T 疗法包括从患者血液中提取 T 细胞，并在实验室中对它们进行基因改造，以产生与癌细胞中丰富的蛋白质结合的受体。 然后大量生产这些经过修饰的 CAR-T 细胞并给予患者。 通过增强 T 细胞发现和攻击癌细胞的能力，CAR-T 疗法有可能彻底改变癌症治疗。

然而，COVID-19 大流行正在影响 CAR-T 细胞治疗市场。 供应链关闭和中断导致 CAR-T 细胞製造所需原材料的生产和供应出现延误和中断。 因此，生命科学和生物製药公司面临着等待用于 CAR-T 细胞製造的新原材料的挑战。 我们正在努力解决这些供应链问题，并确保原材料的稳定供应，以支持在此困难时期的 CAR-T 细胞製造。

CAR-T 细胞治疗市场报告亮点

CD19/CD22是市场份额最大的CAR-T细胞疗法。 它在治疗白血病和淋巴瘤方面表现出出色的临床效果，已获得监管部门批准，并已被证明可有效实现患者缓解。

DLBCL（瀰漫性大B细胞淋巴瘤）是CAR-T细胞治疗市场的一个突出适应症，占据了很大的市场份额。 这种快速生长的 B 细胞来源的癌症是一种影响淋巴系统的非霍奇金淋巴瘤。

在癌症发病率上升和生物技术行业增长的推动下，北美将引领市场。 因此，该地区对癌症治疗的需求也在增加。

全球市场参与者包括：Amgen（美国）、Bellicum Pharmaceuticals（美国）、Bluebird Bio（美国）、Caribou Biosciences（美国）、Celgene、Cellectis、Celyad、Gilead Sciences、Intellia Therapeutics、Johnson &Johnson、Merck KGaA、Nanjing Legend Biotechnology、Noile-Immune Biotech、Novartis International AG、Pfizer Inc.、Sangamo Therapeutics、Servier Laboratories

内容

第一章简介

第 2 章执行摘要

第三章研究方法

第四章全球 CAR-T 细胞治疗市场洞察

  • CAR-T细胞治疗市场-行业概况
  • CAR-T细胞疗法市场动态
    • 驱动因素和机遇
      • 人们对 CAR-T 细胞疗法的认识不断提高
      • 癌症治疗中对理想治疗方法的需求增加
    • 制约因素和问题
      • CAR-T细胞疗法的高成本
  • 杵分析
  • CAR-T细胞治疗行业的趋势
  • 价值链分析
  • COVID-19 的影响分析

第五章全球 CAR-T 细胞治疗市场（按目标抗原）

  • 主要发现
  • 简介
  • CD19/CD22
  • BCMA（B 细胞成熟抗原）
  • 其他（MUC16、L1CAM、ROR1、EGFRvIII、PSCA、NKR-2、IL13Ra2、LewisY）

第 6 章全球 CAR-T 细胞治疗市场（按适应症）

  • 主要发现
  • 简介
  • DLBCL
  • 全部
  • CLL
  • MM
  • 佛罗里达州
  • 乳腺疾病
  • 骨髓纤维化
  • MLL
  • 胸腺癌
  • 胶质母细胞瘤
  • 反洗钱
  • 其他

第 7 章全球 CAR-T 细胞治疗市场（按地区）

  • 主要发现
  • 简介
    • 2019-2032 年 CAR-T 细胞疗法市场评估，地区
  • CAR-T 细胞治疗市场 - 北美
    • 北美：2019-2032 年 CAR-T 细胞治疗市场（按适应症）
    • 北美：2019-2032 年按目标抗原划分的 CAR-T 细胞治疗市场
    • CAR-T细胞治疗市场-美国
    • CAR-T 细胞治疗市场 - 加拿大
  • CAR-T 细胞治疗市场 - 欧洲
    • 欧洲：2019-2032 年 CAR-T 细胞疗法市场（按适应症）
    • 欧洲：2019-2032 年 CAR-T 细胞治疗市场（按目标抗原）
    • CAR-T 细胞治疗市场 - 英国
    • CAR-T 细胞治疗市场 - 法国
    • CAR-T 细胞治疗市场 - 德国
    • CAR-T 细胞治疗市场 - 意大利
    • CAR-T 细胞治疗市场 - 西班牙
    • CAR-T 细胞治疗市场 - 荷兰
    • CAR-T 细胞治疗市场 - 俄罗斯
  • CAR-T 细胞治疗市场 - 亚太地区
    • 亚太地区：CAR-T 细胞治疗市场，按适应症划分，2019-2032 年
    • 亚太地区：2019-2032 年按目标抗原划分的 CAR-T 细胞治疗市场
    • CAR-T细胞治疗市场——中国
    • CAR-T 细胞治疗市场 - 印度
    • CAR-T 细胞治疗市场 - 马来西亚
    • CAR-T 细胞治疗市场 - 日本
    • CAR-T 细胞治疗市场 - 印度尼西亚
    • CAR-T 细胞治疗市场 - 韩国
  • CAR-T细胞治疗市场-中东和非洲
    • 中东和非洲：2019-2032 年 CAR-T 细胞治疗市场（按适应症）
    • 中东和非洲：2019-2032 年按目标抗原划分的 CAR-T 细胞治疗市场
    • CAR-T 细胞治疗市场 - 沙特阿拉伯
    • CAR-T细胞治疗市场——阿拉伯联合酋长国
    • CAR-T 细胞治疗市场 - 以色列
    • CAR-T 细胞治疗市场 - 南非
  • CAR-T 细胞治疗市场 - 拉丁美洲
    • 拉丁美洲：CAR-T 细胞治疗市场，按适应症划分，2019-2032 年
    • 拉丁美洲：2019-2032 年按目标抗原划分的 CAR-T 细胞治疗市场
    • CAR-T细胞治疗市场——墨西哥
    • CAR-T 细胞治疗市场 - 巴西
    • CAR-T细胞治疗市场-阿根廷

第 8 章竞争格局

  • 扩张和收购分析
    • 扩展名
    • 收购
  • 伙伴关係/协作/协议/披露

第 9 章公司简介

  • Amgen Inc.（US）
  • Bellicum Pharmaceuticals, Inc
  • Bellicum Pharmaceuticals, Inc.（US）
  • Bluebird Bio（US）
  • Caribou Biosciences, Inc.（US）
  • Cellectis
  • Celyad
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Johnson & Johnson
  • Merck KGaA
  • Nanjing Legend Biotechnology Co., Ltd
  • Noile-Immune Biotech
  • Novartis International AG
  • Pfizer Inc
  • Sangamo Therapeutics, Inc
  • Servier Laboratories
Product Code: PM1389

The global CAR-T cell therapy market size is expected to reach USD 118,680.68 million by 2032, according to a new study by Polaris Market Research. The report "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report, By Target Antigen (CD19/CD22, BCMA, and Others); By Indication; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The CAR-T cell therapy market is experiencing significant growth as it utilizes the immune system to combat cancer. This groundbreaking approach involves modifying a patient's own T cells, a type of white blood cell, to express chimeric antigen receptors (CARs) on their surface. These CARs enable the T cells to recognize and target specific antigens in cancer cells, leading to their destruction. CAR-T therapy has shown promising results in treating specific blood malignancies and is being explored for its potential in other types of cancer.

In CAR-T treatment, T cells from the patient's blood are taken out and genetically modified in a lab to produce receptors that bind to proteins prevalent in cancer cells. Large quantities of these modified CAR-T cells are then produced and administered to the patient. By enhancing the T cells' ability to locate and attack cancer cells, CAR-T therapy has the potential to revolutionize cancer treatment.

However, the COVID-19 pandemic has impacted the CAR-T cell therapy market. Lockdowns and disruptions in the supply chain have resulted in delays and interruptions in the production and availability of raw materials needed for CAR-T cell manufacturing. This has created challenges for life science and biopharma companies, causing them to wait for new raw materials for CAR-T cell production. Efforts are underway to address these supply chain issues and ensure a steady supply of materials to support the manufacturing of CAR-T cells during these challenging times.

CAR-T Cell Therapy Market Report Highlights

CD19/CD22 is the CAR-T cell therapy with the largest market share. It has shown remarkable clinical results in leukemia and lymphoma treatment, gaining regulatory approval and proving effective in achieving patient remission.

DLBCL (Diffuse Large B-cell Lymphoma) is a prominent indication in the CAR-T cell therapy market, holding a significant market share. This fast-growing cancer of B-cell origin is a prevalent form of non-Hodgkin lymphoma affecting the lymphatic system.

North America is set to lead the market, driven by rising cancer incidence and the growing biotechnology industry. The region's demand for cancer treatments is increasing accordingly.

The global key market players include: Amgen Inc. (US), Bellicum Pharmaceuticals, Inc. (US), Bluebird Bio (US), Caribou Biosciences, Inc. (US), Celgene Corporation, Cellectis, Celyad, Gilead Sciences, Inc., Intellia Therapeutics, Johnson & Johnson, Merck KGaA, Nanjing Legend Biotechnology Co., Ltd., Noile-Immune Biotech, Novartis International AG, Pfizer Inc., Sangamo Therapeutics, Inc., Servier Laboratories.

Polaris Market Research has segmented the CAR-T Cell Therapy market report based on target antigen, indication, and region:

CAR-T Cell Therapy, Target Antigen Outlook (Revenue - USD Million, 2019 - 2032)

  • CD19/CD22
  • BCMA (B-Cell Maturation Antigen)
  • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)

CAR-T Cell Therapy, Indication Outlook (Revenue - USD Million, 2019 - 2032)

  • DLBCL
  • ALL
  • CLL
  • MM
  • FL
  • Mastozytosis
  • Myeloid Fibrosis
  • MLL
  • Thymic Cancer
  • Glioblastoma
  • AML
  • Others

CAR-T Cell Therapy, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Austria
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global CAR-T Cell Therapy Market Insights

  • 4.1. CAR-T Cell Therapy Market - Industry Snapshot
  • 4.2. CAR-T Cell Therapy Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in awareness regarding CAR T-cell therapy
      • 4.2.1.2. Increase in demand of ideal therapeutics for treatment of cancer
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of CAR T-cell therapies
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. CAR-T Cell Therapy Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global CAR-T Cell Therapy Market, by Target Antigen

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global CAR-T Cell Therapy, by Target Antigen, 2019-2032 (USD Million)
  • 5.3. CD19/CD22
    • 5.3.1. Global CAR-T Cell Therapy Market, by CD19/CD22, by Region, 2019-2032 (USD Million)
  • 5.4. BCMA (B-Cell Maturation Antigen)
    • 5.4.1. Global CAR-T Cell Therapy Market, by BCMA (B-Cell Maturation Antigen), by Region, 2019-2032 (USD Million)
  • 5.5. Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
    • 5.5.1. Global CAR-T Cell Therapy Market, by Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY), by Region, 2019-2032 (USD Million)

6. Global CAR-T Cell Therapy Market, by Indication

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • 6.3. DLBCL
    • 6.3.1. Global CAR-T Cell Therapy Market, by DLBCL, by Region, 2019-2032 (USD Million)
  • 6.4. ALL
    • 6.4.1. Global CAR-T Cell Therapy Market, by ALL, by Region, 2019-2032 (USD Million)
  • 6.5. CLL
    • 6.5.1. Global CAR-T Cell Therapy Market, by CLL, by Region, 2019-2032 (USD Million)
  • 6.6. MM
    • 6.6.1. Global CAR-T Cell Therapy Market, by MM, by Region, 2019-2032 (USD Million)
  • 6.7. FL
    • 6.7.1. Global CAR-T Cell Therapy Market, by FL, by Region, 2019-2032 (USD Million)
  • 6.8. Mastozytosis
    • 6.8.1. Global CAR-T Cell Therapy Market, by Mastozytosis, by Region, 2019-2032 (USD Million)
  • 6.9. Myeloid Fibrosis
    • 6.9.1. Global CAR-T Cell Therapy Market, by Myeloid Fibrosis, by Region, 2019-2032 (USD Million)
  • 6.10. MLL
    • 6.10.1. Global CAR-T Cell Therapy Market, by MLL, by Region, 2019-2032 (USD Million)
  • 6.11. Thymic Cancer
    • 6.11.1. Global CAR-T Cell Therapy Market, by Thymic Cancer, by Region, 2019-2032 (USD Million)
  • 6.12. Glioblastoma
    • 6.12.1. Global CAR-T Cell Therapy Market, by Glioblastoma, by Region, 2019-2032 (USD Million)
  • 6.13. AML
    • 6.13.1. Global CAR-T Cell Therapy Market, by AML, by Region, 2019-2032 (USD Million)
  • 6.14. Others
    • 6.14.1. Global CAR-T Cell Therapy Market, by Others, by Region, 2019-2032 (USD Million)

7. Global CAR-T Cell Therapy Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. CAR-T Cell Therapy Market Assessment, By Geography, 2019-2032 (USD Million)
  • 7.3. CAR-T Cell Therapy Market - North America
    • 7.3.1. North America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.3.2. North America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.3.3. CAR-T Cell Therapy Market - U.S.
      • 7.3.3.1. U.S.: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.3.3.2. U.S.: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.3.4. CAR-T Cell Therapy Market - Canada
      • 7.3.4.1. Canada: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.3.4.2. Canada: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.4. CAR-T Cell Therapy Market - Europe
    • 7.4.1. Europe: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.4.2. Europe: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.3. CAR-T Cell Therapy Market - UK
      • 7.4.3.1. UK: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.3.2. UK: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.4. CAR-T Cell Therapy Market - France
      • 7.4.4.1. France: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.4.2. France: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.5. CAR-T Cell Therapy Market - Germany
      • 7.4.5.1. Germany: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.5.2. Germany: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.6. CAR-T Cell Therapy Market - Italy
      • 7.4.6.1. Italy: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.6.2. Italy: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.7. CAR-T Cell Therapy Market - Spain
      • 7.4.7.1. Spain: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.7.2. Spain: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.8. CAR-T Cell Therapy Market - Netherlands
      • 7.4.8.1. Netherlands: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.8.2. Netherlands: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.4.9. CAR-T Cell Therapy Market - Russia
      • 7.4.9.1. Russia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.4.9.2. Russia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.5. CAR-T Cell Therapy Market - Asia Pacific
    • 7.5.1. Asia Pacific: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.5.2. Asia Pacific: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.3. CAR-T Cell Therapy Market - China
      • 7.5.3.1. China: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.3.2. China: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.4. CAR-T Cell Therapy Market - India
      • 7.5.4.1. India: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.4.2. India: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.5. CAR-T Cell Therapy Market - Malaysia
      • 7.5.5.1. Malaysia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.5.2. Malaysia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.6. CAR-T Cell Therapy Market - Japan
      • 7.5.6.1. Japan: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.6.2. Japan: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.7. CAR-T Cell Therapy Market - Indonesia
      • 7.5.7.1. Indonesia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.7.2. Indonesia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.5.8. CAR-T Cell Therapy Market - South Korea
      • 7.5.8.1. South Korea: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.5.8.2. South Korea: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.6. CAR-T Cell Therapy Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.6.2. Middle East & Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.3. CAR-T Cell Therapy Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.3.2. Saudi Arabia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.4. CAR-T Cell Therapy Market - UAE
      • 7.6.4.1. UAE: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.4.2. UAE: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.5. CAR-T Cell Therapy Market - Israel
      • 7.6.5.1. Israel: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.5.2. Israel: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.6.6. CAR-T Cell Therapy Market - South Africa
      • 7.6.6.1. South Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.6.6.2. South Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • 7.7. CAR-T Cell Therapy Market - Latin America
    • 7.7.1. Latin America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
    • 7.7.2. Latin America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.7.3. CAR-T Cell Therapy Market - Mexico
      • 7.7.3.1. Mexico: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.7.3.2. Mexico: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.7.4. CAR-T Cell Therapy Market - Brazil
      • 7.7.4.1. Brazil: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.7.4.2. Brazil: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
    • 7.7.5. CAR-T Cell Therapy Market - Argentina
      • 7.7.5.1. Argentina: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
      • 7.7.5.2. Argentina: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Amgen Inc. (US)
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bellicum Pharmaceuticals, Inc
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bellicum Pharmaceuticals, Inc. (US)
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bluebird Bio (US)
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Caribou Biosciences, Inc. (US)
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Cellectis
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Celyad
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Gilead Sciences, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Intellia Therapeutics
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Johnson & Johnson
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Merck KGaA
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Nanjing Legend Biotechnology Co., Ltd
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Noile-Immune Biotech
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Novartis International AG
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Pfizer Inc
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. Sangamo Therapeutics, Inc
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Servier Laboratories
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development

List of Tables

  • Table 1 Global CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 2 Global CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 3 CAR-T Cell Therapy Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 4 North America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 5 North America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 6 U.S.: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 7 U.S.: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 8 Canada: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 9 Canada: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 10 Europe: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 11 Europe: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 12 UK: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 13 UK: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 14 France: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 15 France: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 16 Germany: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 17 Germany: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 18 Italy: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 19 Italy: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 20 Spain: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 21 Spain: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 22 Netherlands: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 23 Netherlands: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 24 Russia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 25 Russia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 26 Asia Pacific: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 27 Asia Pacific: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 28 China: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 29 China: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 30 India: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 31 India: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 32 Malaysia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 33 Malaysia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 34 Japan: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 35 Japan: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 36 Indonesia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 37 Indonesia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 38 South Korea: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 39 South Korea: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 40 Middle East & Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 41 Middle East & Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 42 Saudi Arabia: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 43 Saudi Arabia: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 44 UAE: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 45 UAE: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 46 Israel: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 47 Israel: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 48 South Africa: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 49 South Africa: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 50 Latin America: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 51 Latin America: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 52 Mexico: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 53 Mexico: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 54 Brazil: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 55 Brazil: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)
  • Table 56 Argentina: CAR-T Cell Therapy Market, by Indication, 2019-2032 (USD Million)
  • Table 57 Argentina: CAR-T Cell Therapy Market, by Target Antigen, 2019-2032 (USD Million)

List of Figures

  • Figure 1 Global CAR-T Cell Therapy Market, 2019-2032 (USD Million)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Indication
  • Figure 7 Global CAR-T Cell Therapy Market, by Indication, 2022 & 2032 (USD Million)
  • Figure 8 Market by Target Antigen
  • Figure 9 Global CAR-T Cell Therapy Market, by Target Antigen, 2022 & 2032 (USD Million)
  • Figure 10 CAR-T Cell Therapy Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 11 Strategic Analysis - CAR-T Cell Therapy Market